Open main menu

Oldest pages

Showing below up to 250 results in range #201 to #450.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

  1. Air-kerma, incident‏‎ (17:32, 12 September 2019)
  2. Air-kerma, product‏‎ (17:33, 12 September 2019)
  3. Alimentary tract transfer factor‏‎ (17:34, 12 September 2019)
  4. Alpha decay‏‎ (17:35, 12 September 2019)
  5. Alveolar-interstitial region‏‎ (17:35, 12 September 2019)
  6. Angiogenesis‏‎ (17:35, 12 September 2019)
  7. Annihilation photons‏‎ (17:36, 12 September 2019)
  8. Annual dose‏‎ (17:36, 12 September 2019)
  9. Area monitoring‏‎ (17:37, 12 September 2019)
  10. Auger transition‏‎ (17:37, 12 September 2019)
  11. Authorization‏‎ (17:38, 12 September 2019)
  12. Authorized limit‏‎ (17:38, 12 September 2019)
  13. Autoimmune disease‏‎ (17:39, 12 September 2019)
  14. Autonomy‏‎ (17:39, 12 September 2019)
  15. Averted dose‏‎ (17:40, 12 September 2019)
  16. Wisdom‏‎ (17:43, 12 September 2019)
  17. Waste disposal‏‎ (17:43, 12 September 2019)
  18. Background dose (rate)‏‎ (18:55, 12 September 2019)
  19. Basal cell‏‎ (18:56, 12 September 2019)
  20. Benthic‏‎ (18:57, 12 September 2019)
  21. Beta-minus decay‏‎ (18:57, 12 September 2019)
  22. Beta-plus decay‏‎ (18:58, 12 September 2019)
  23. Biomedical research volunteer‏‎ (18:58, 12 September 2019)
  24. Bioturbation‏‎ (18:59, 12 September 2019)
  25. Bone marrow‏‎ (18:59, 12 September 2019)
  26. Bradycardia‏‎ (18:59, 12 September 2019)
  27. Branching fraction‏‎ (18:59, 12 September 2019)
  28. Bronchial region‏‎ (19:00, 12 September 2019)
  29. Bystander effect‏‎ (19:00, 12 September 2019)
  30. Qualified expert‏‎ (19:03, 12 September 2019)
  31. Occupational exposure‏‎ (19:07, 12 September 2019)
  32. Orphan source‏‎ (19:07, 12 September 2019)
  33. Oversight‏‎ (19:07, 12 September 2019)
  34. Cardiac arrhythmias‏‎ (19:15, 12 September 2019)
  35. Cardiac valve diseases‏‎ (19:16, 12 September 2019)
  36. Cardiomyopathy‏‎ (19:16, 12 September 2019)
  37. Cardioverter-defibrillator‏‎ (19:16, 12 September 2019)
  38. Chronic exposure‏‎ (19:17, 12 September 2019)
  39. Class SR-0 gases‏‎ (19:17, 12 September 2019)
  40. Class SR-1 gases‏‎ (19:17, 12 September 2019)
  41. Class SR-2 gases‏‎ (19:18, 12 September 2019)
  42. Clearance level‏‎ (19:19, 12 September 2019)
  43. Clonogenic cells‏‎ (19:19, 12 September 2019)
  44. Clonogenic survival‏‎ (19:19, 12 September 2019)
  45. Co-expertise‏‎ (19:19, 12 September 2019)
  46. Colony‏‎ (19:20, 12 September 2019)
  47. Committed effective dose‏‎ (19:20, 12 September 2019)
  48. Committed equivalent dose‏‎ (19:20, 12 September 2019)
  49. Complex tissues‏‎ (19:21, 12 September 2019)
  50. Computed tomography dose index‏‎ (19:21, 12 September 2019)
  51. Connective tissue‏‎ (19:21, 12 September 2019)
  52. Consequential late effects‏‎ (19:21, 12 September 2019)
  53. Constancy test‏‎ (19:21, 12 September 2019)
  54. Contamination‏‎ (19:22, 12 September 2019)
  55. Coronary heart disease‏‎ (19:23, 12 September 2019)
  56. Cost-benefit analysis‏‎ (19:24, 12 September 2019)
  57. Coster-Kronig transition‏‎ (19:25, 12 September 2019)
  58. Curie‏‎ (19:25, 12 September 2019)
  59. Cytokines‏‎ (19:26, 12 September 2019)
  60. Decay constant‏‎ (19:28, 12 September 2019)
  61. Decommissioning‏‎ (19:28, 12 September 2019)
  62. Decontamination‏‎ (19:29, 12 September 2019)
  63. Decontamination factor‏‎ (19:29, 12 September 2019)
  64. Deontological Ethics‏‎ (19:30, 12 September 2019)
  65. Diastasis‏‎ (19:30, 12 September 2019)
  66. Dichotomous‏‎ (19:31, 12 September 2019)
  67. Differentiation‏‎ (19:31, 12 September 2019)
  68. In vivo radiobioassay‏‎ (19:32, 12 September 2019)
  69. Disposal‏‎ (19:33, 12 September 2019)
  70. DNA damage signalling‏‎ (19:33, 12 September 2019)
  71. Dose constraint‏‎ (19:35, 12 September 2019)
  72. Dose criteria‏‎ (19:35, 12 September 2019)
  73. Dose limit‏‎ (19:36, 12 September 2019)
  74. Dose per unit intake coefficient‏‎ (19:37, 12 September 2019)
  75. Dose rate‏‎ (19:38, 12 September 2019)
  76. Dose rate effectiveness factor‏‎ (19:38, 12 September 2019)
  77. Dose-rate effect‏‎ (19:39, 12 September 2019)
  78. Dose-threshold‏‎ (19:40, 12 September 2019)
  79. Early normal tissue responses‏‎ (19:43, 12 September 2019)
  80. Edema‏‎ (19:44, 12 September 2019)
  81. Effect Dose 50‏‎ (19:45, 12 September 2019)
  82. Effective charge number‏‎ (19:46, 12 September 2019)
  83. Effective dose equivalent‏‎ (19:47, 12 September 2019)
  84. Effective half-life‏‎ (19:49, 12 September 2019)
  85. Electron-capture decay‏‎ (19:49, 12 September 2019)
  86. Electrophysiology‏‎ (19:51, 12 September 2019)
  87. Emergency‏‎ (19:52, 12 September 2019)
  88. Emergency exposure situation‏‎ (19:52, 12 September 2019)
  89. Emergency plan‏‎ (19:53, 12 September 2019)
  90. Emergency preparedness‏‎ (19:53, 12 September 2019)
  91. Emergency procedures‏‎ (19:53, 12 September 2019)
  92. Endogeneous excretion‏‎ (19:54, 12 September 2019)
  93. Environmental exposure‏‎ (19:55, 12 September 2019)
  94. Environmental radiation protection‏‎ (19:55, 12 September 2019)
  95. Epithelium‏‎ (19:56, 12 September 2019)
  96. Erythropoietin‏‎ (19:57, 12 September 2019)
  97. Ethics‏‎ (19:58, 12 September 2019)
  98. Exempt waste‏‎ (19:59, 12 September 2019)
  99. Exemption level‏‎ (19:59, 12 September 2019)
  100. Existing exposure situation‏‎ (20:00, 12 September 2019)
  101. Exponential survival curve‏‎ (20:01, 12 September 2019)
  102. Exposure, external or internal‏‎ (20:01, 12 September 2019)
  103. Exposure situation‏‎ (20:02, 12 September 2019)
  104. Habitual mouth breather‏‎ (12:42, 13 September 2019)
  105. Habitual nose breather‏‎ (12:42, 13 September 2019)
  106. Half-life, physical‏‎ (12:43, 13 September 2019)
  107. Hazard‏‎ (12:43, 13 September 2019)
  108. Health Surveillance‏‎ (12:43, 13 September 2019)
  109. Heliosphere‏‎ (12:44, 13 September 2019)
  110. Hierarchical tissues‏‎ (12:44, 13 September 2019)
  111. High level waste‏‎ (12:45, 13 September 2019)
  112. Hormones‏‎ (12:45, 13 September 2019)
  113. Hyperbaric oxygen‏‎ (12:46, 13 September 2019)
  114. Hypertrophic cardiomyopathy‏‎ (12:48, 13 September 2019)
  115. Hypoplasia‏‎ (12:48, 13 September 2019)
  116. Immune system‏‎ (12:49, 13 September 2019)
  117. Incident‏‎ (12:50, 13 September 2019)
  118. Inclusiveness‏‎ (12:50, 13 September 2019)
  119. Individual decontamination‏‎ (12:50, 13 September 2019)
  120. Individual monitoring‏‎ (12:51, 13 September 2019)
  121. Individual-related‏‎ (12:51, 13 September 2019)
  122. Inhalability‏‎ (12:53, 13 September 2019)
  123. Inner bremsstrahlung‏‎ (12:53, 13 September 2019)
  124. Institutional control‏‎ (12:54, 13 September 2019)
  125. Intermediate level waste‏‎ (12:54, 13 September 2019)
  126. Internal conversion electron‏‎ (12:56, 13 September 2019)
  127. Interphase death‏‎ (12:56, 13 September 2019)
  128. Intervention Level‏‎ (12:56, 13 September 2019)
  129. Interventional procedure‏‎ (12:57, 13 September 2019)
  130. Iso-effect plots‏‎ (12:58, 13 September 2019)
  131. Isomers‏‎ (12:58, 13 September 2019)
  132. Isotropic geometry‏‎ (12:58, 13 September 2019)
  133. Itinerant (radiation) worker‏‎ (12:59, 13 September 2019)
  134. Latent time/period or latency interval‏‎ (13:01, 13 September 2019)
  135. Limitation of dose‏‎ (13:01, 13 September 2019)
  136. Lineal energy‏‎ (13:02, 13 September 2019)
  137. Linear-non-threshold model‏‎ (13:03, 13 September 2019)
  138. Low level waste‏‎ (13:08, 13 September 2019)
  139. Lymphatic system‏‎ (13:08, 13 September 2019)
  140. Macrophage colony stimulating factor‏‎ (13:08, 13 September 2019)
  141. Magnetosphere‏‎ (13:09, 13 September 2019)
  142. Member of the public‏‎ (13:10, 13 September 2019)
  143. Mendelian diseases‏‎ (13:10, 13 September 2019)
  144. Mitigation‏‎ (13:10, 13 September 2019)
  145. Multistage tumorigenesis‏‎ (13:11, 13 September 2019)
  146. Myocardial perfusion‏‎ (13:12, 13 September 2019)
  147. Myocardial stress test‏‎ (13:13, 13 September 2019)
  148. Naturally occurring radioactive material‏‎ (13:14, 13 September 2019)
  149. Necrosis‏‎ (13:14, 13 September 2019)
  150. Neurological syndrome‏‎ (13:14, 13 September 2019)
  151. Neurovascular syndrome‏‎ (13:15, 13 September 2019)
  152. Non-sphericity parameter‏‎ (13:16, 13 September 2019)
  153. Nuclear track detectors‏‎ (13:17, 13 September 2019)
  154. Particle radiance‏‎ (13:28, 13 September 2019)
  155. Peak skin dose‏‎ (13:28, 13 September 2019)
  156. Pelagic‏‎ (13:29, 13 September 2019)
  157. Percutaneous coronary intervention‏‎ (13:29, 13 September 2019)
  158. Pericarditis‏‎ (13:29, 13 September 2019)
  159. Pharynx‏‎ (13:30, 13 September 2019)
  160. Planned exposure situation‏‎ (13:30, 13 September 2019)
  161. Platelet-derived growth factor‏‎ (13:30, 13 September 2019)
  162. Practical radiological protection culture‏‎ (13:32, 13 September 2019)
  163. Prevailing circumstances‏‎ (13:32, 13 September 2019)
  164. Principle of application of dose limits‏‎ (13:32, 13 September 2019)
  165. Principle of justification‏‎ (13:33, 13 September 2019)
  166. Principle of optimisation‏‎ (13:33, 13 September 2019)
  167. Procedural values‏‎ (13:34, 13 September 2019)
  168. Progenitor cell‏‎ (13:35, 13 September 2019)
  169. Projected dose‏‎ (13:36, 13 September 2019)
  170. Protection strategy‏‎ (13:37, 13 September 2019)
  171. Protective action‏‎ (13:37, 13 September 2019)
  172. Protective action guide‏‎ (13:38, 13 September 2019)
  173. Public exposure‏‎ (13:39, 13 September 2019)
  174. Radiation modifier‏‎ (13:41, 13 September 2019)
  175. Radiation safety officer‏‎ (13:42, 13 September 2019)
  176. Radiation worker‏‎ (13:44, 13 September 2019)
  177. Radioactive dispersion device‏‎ (13:44, 13 September 2019)
  178. Radioactive source‏‎ (13:45, 13 September 2019)
  179. Radioactive substance‏‎ (13:46, 13 September 2019)
  180. Radioactivity‏‎ (13:46, 13 September 2019)
  181. Radiofrequency ablation‏‎ (13:46, 13 September 2019)
  182. Radiographer‏‎ (13:48, 13 September 2019)
  183. Radiological protection principles‏‎ (13:49, 13 September 2019)
  184. Radionuclides of natural origin‏‎ (13:49, 13 September 2019)
  185. Radioresponsiveness‏‎ (13:49, 13 September 2019)
  186. Radiosensitiser‏‎ (13:50, 13 September 2019)
  187. Radiosensitivity, cellular‏‎ (13:50, 13 September 2019)
  188. Reasonableness‏‎ (13:50, 13 September 2019)
  189. Recovery‏‎ (13:51, 13 September 2019)
  190. Recovery responder‏‎ (13:51, 13 September 2019)
  191. Reference bioassay function‏‎ (13:51, 13 September 2019)
  192. Reference biokinetic model‏‎ (13:52, 13 September 2019)
  193. Reference level‏‎ (13:52, 13 September 2019)
  194. Rehabilitation of living conditions‏‎ (13:52, 13 September 2019)
  195. Relocation‏‎ (13:53, 13 September 2019)
  196. Remedial action‏‎ (13:53, 13 September 2019)
  197. Remediation‏‎ (13:53, 13 September 2019)
  198. Repopulation‏‎ (13:54, 13 September 2019)
  199. Representative organism (non-human biota)‏‎ (13:54, 13 September 2019)
  200. Representative person‏‎ (13:54, 13 September 2019)
  201. Reproductive integrity‏‎ (13:55, 13 September 2019)
  202. Residual dose‏‎ (13:55, 13 September 2019)
  203. Respiratory protection‏‎ (13:55, 13 September 2019)
  204. Retrievability‏‎ (13:56, 13 September 2019)
  205. Reversibility‏‎ (13:56, 13 September 2019)
  206. Right to know‏‎ (13:57, 13 September 2019)
  207. Rigidity‏‎ (13:58, 13 September 2019)
  208. Routine monitoring‏‎ (13:58, 13 September 2019)
  209. Safety case‏‎ (13:59, 13 September 2019)
  210. Safety culture‏‎ (13:59, 13 September 2019)
  211. Scintigraphy‏‎ (13:59, 13 September 2019)
  212. Self-help protection‏‎ (14:00, 13 September 2019)
  213. Slow repair‏‎ (14:01, 13 September 2019)
  214. Solar cosmic radiation‏‎ (14:01, 13 September 2019)
  215. Solar cycle‏‎ (14:01, 13 September 2019)
  216. Solar particle event‏‎ (14:01, 13 September 2019)
  217. Source term‏‎ (14:02, 13 September 2019)
  218. Source-related‏‎ (14:02, 13 September 2019)
  219. South Atlantic anomaly‏‎ (14:03, 13 September 2019)
  220. Special (non-routine) monitoring‏‎ (14:03, 13 September 2019)
  221. Spontaneous fission‏‎ (14:03, 13 September 2019)
  222. Stakeholder‏‎ (14:04, 13 September 2019)
  223. Stenosis‏‎ (14:04, 13 September 2019)
  224. Storage‏‎ (14:04, 13 September 2019)
  225. Subcutaneous tissue‏‎ (14:05, 13 September 2019)
  226. Substantial radiation dose level‏‎ (14:05, 13 September 2019)
  227. Systemic model‏‎ (14:06, 13 September 2019)
  228. Tachycardia‏‎ (14:10, 13 September 2019)
  229. Target region‏‎ (14:10, 13 September 2019)
  230. Target tissue‏‎ (14:10, 13 September 2019)
  231. Telangiectasia‏‎ (14:11, 13 September 2019)
  232. Threshold dose for tissue reactions‏‎ (14:11, 13 September 2019)
  233. Thyroid blocking‏‎ (14:11, 13 September 2019)
  234. Time factor‏‎ (14:11, 13 September 2019)
  235. Tissue equivalent material‏‎ (14:12, 13 September 2019)
  236. Tolerability‏‎ (14:12, 13 September 2019)
  237. Track structure‏‎ (14:13, 13 September 2019)
  238. Transfer compartment‏‎ (14:14, 13 September 2019)
  239. Transfer rate‏‎ (14:14, 13 September 2019)
  240. Transforming growth factor‏‎ (14:15, 13 September 2019)
  241. Transparency‏‎ (14:15, 13 September 2019)
  242. Trapped particles‏‎ (14:16, 13 September 2019)
  243. Types of materials‏‎ (14:16, 13 September 2019)
  244. Application of ionising radiation in healthcare (old)‏‎ (18:00, 9 October 2019)
  245. Information for patients, family members, carers and the public (old)‏‎ (18:00, 9 October 2019)
  246. Information for healthcare providers (old)‏‎ (18:00, 9 October 2019)
  247. Application of ionising radiation in healthcare‏‎ (18:04, 9 October 2019)
  248. Information for patients, family members, carers and the public‏‎ (18:11, 9 October 2019)
  249. Information for healthcare providers‏‎ (18:21, 9 October 2019)
  250. ICRPædia Guides‏‎ (18:33, 9 October 2019)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)